Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2025
Date Filed: March 14, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed in this filing is the submission of Exhibit 99.1, titled "Becoming a substantial holder." This indicates a change in ownership structure where a party has acquired a significant stake in the company.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the notification of the substantial holder event.
Investor Verification Checklist
- Review Exhibit 99.1 to identify the new substantial holder and the percentage of shares acquired.
- Verify the impact of this ownership change on the company's governance or strategic direction.
- Confirm the company's status as a development stage enterprise and its current cash runway, as no financial data is included in this specific filing.